MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $100.00 price target on the stock. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.62) EPS.

Several other analysts have also recently commented on MLTX. Wedbush restated an “outperform” rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. The Goldman Sachs Group upgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $62.00 to $82.00 in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $83.20.

MoonLake Immunotherapeutics Stock Down 0.0 %

MLTX stock opened at $41.76 on Thursday. The firm has a 50 day moving average of $46.49 and a 200 day moving average of $48.91. The stock has a market capitalization of $2.67 billion, a PE ratio of -32.37 and a beta of 1.28. MoonLake Immunotherapeutics has a 52 week low of $37.55 and a 52 week high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09). On average, equities research analysts expect that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. US Bancorp DE acquired a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter valued at about $44,000. Deutsche Bank AG boosted its position in shares of MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company’s stock valued at $49,000 after acquiring an additional 338 shares during the last quarter. Birchview Capital LP acquired a new position in shares of MoonLake Immunotherapeutics during the 4th quarter valued at about $217,000. KLP Kapitalforvaltning AS acquired a new position in shares of MoonLake Immunotherapeutics during the 4th quarter valued at about $244,000. Finally, PEAK6 LLC acquired a new position in shares of MoonLake Immunotherapeutics during the 4th quarter valued at about $271,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.